Abstract: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a carbohydrate; or a steroid, e.g., cholesterol, which is optionally substituted with at least one carbohydrate. is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.

Abstract: This invention relates to modified double-stranded oligoribonucleic acid (dsRNA) having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene.

Abstract: Load sharing clusters in which each node is responsible for one or more non-overlapping subset(s) of the cluster namespace and will process only those requests that access file or directory objects in the partitioned namespace that the node controls while redirecting requests designated for other nodes. A non-overlapping subset may be migrated from a source node to a destination node, for example, for load sharing or hotspot mitigation. Migration typically includes maintaining a file virtualization link from the destination node to the source node to permit forwarding of requests by the destination node to the source node during migration of metadata and then migration of data from the source node. After migration is complete, the file virtualization link is broken and the destination node services requests for the non-overlapping subset from the migrated metadata and data.

Abstract: A non-distruptive migration of a native volume from a source server to a destination server performed by a file switch involves converting the source native volume to a native with metadata volume. The native with metadata volume is converted to a mirrored native with metadata volume including the source server and the destination server. The destination server includes a mirror copy of the native with metadata volume. The source server is removed from the mirrored native with metadata volume. The mirror copy of the native with metadata volume on the destination server is converted to a destination native volume on the destination server.

Abstract: A method and system for efficient direct DMA for processing connection state information or other expediting data packets. One example is the use of a network interface controller to buffer TCP type data packets that may contain connection state information. The connection state information is extracted from a received packet. The connection state information is stored in a special DMA descriptor that is stored in a ring buffer area of a buffer memory that is accessible by a host processor when an interrupt signal is received. The packet is then discarded. The host processor accesses the ring buffer memory only to retrieve the stored connection state information from the DMA descriptor without having to access a packet buffer area in the memory.

Abstract: Therapeutic sRNA agents and methods of making and using are enclosed.

Abstract: The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(RN) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z?)(Z?)O-nucleoside, —P(Z?)(Z?)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z?)(Z?)O-Linker-OP(Z??)(Z??)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z?)(Z?)-formula (I), —P(Z?)(Z?)— or -Linker-R; R is LG, -Linker-LG, or has the structure shown below: LG is independently for each occurrence a carbohydrate, e.g.

Abstract: The present invention provides for a method of producing an integral multilayered porous membrane by simultaneously co-casting a plurality of polymer solutions onto a support to form a multilayered liquid sheet and immersing the sheet into a liquid coagulation bath to effect phase separation and form a porous membrane. The support can be a temporary support or form an integrated support for the membrane. The plurality of layers may be of the same polymer or different, same concentration or viscosity or different and may be subjected to the same processing conditions or different ones to form unique structures.

Abstract: The present invention relates to processes and reagents for oligonucleotide synthesis and purification. One aspect of the present invention relates to compounds useful for activating phosphoramidites in oligonucleotide synthesis. Another aspect of the present invention relates to a method of preparing oligonucleotides via the phosphoramidite method using an activator of the invention. Another aspect of the present invention relates to sulfur-transfer agents. In a preferred embodiment, the sulfur-transfer agent is a 3-amino-1,2,4-dithiazolidine-5-one. Another aspect of the present invention relates to a method of preparing a phosphorothioate by treating a phosphite with a sulfur-transfer reagent of the invention. In a preferred embodiment, the sulfur-transfer agent is a 3-amino-1,2,4-dithiazolidine-5-one. Another aspect of the present invention relates to compounds that scavenge acrylonitrile produced during the deprotection of phosphate groups bearing ethylnitrile protecting groups.

Abstract: A drive system and methods thereof include at least one actuator assembly that detachably engages a moveable system and at least one control system. The control system voltage biases the actuator assembly in at least one direction at a rate which causes the at least one actuator assembly to slip with respect to the detachably engaged moveable system. The control system also voltage biases the actuator assembly in at least one other direction at a rate which causes the at least one actuator assembly to stick and move with respect to the detachably engaged moveable system.

Abstract: The present invention relates to processes and reagents for oligonucleotide synthesis and purification. One aspect of the present invention relates to compounds useful for activating phosphoramidites in oligonucleotide synthesis. Another aspect of the present invention relates to a method of preparing oligonucleotides via the phosphoramidite method using an activator of the invention. Another aspect of the present invention relates to sulfur-transfer agents. In a preferred embodiment, the sulfur-transfer agent is a 3-amino-1,2,4-dithiazolidine-5-one. Another aspect of the present invention relates to a method of preparing a phosphorothioate by treating a phosphite with a sulfur-transfer reagent of the invention. In a preferred embodiment, the sulfur-transfer agent is a 3-amino-1,2,4-dithiazolidine-5-one. Another aspect of the present invention relates to compounds that scavenge acrylonitrile produced during the deprotection of phosphate groups bearing ethylnitrile protecting groups.

Abstract: The present invention relates to a photolabile compound including a coumarin family caging group covalently bound to an organic moiety containing a carboxyl group, an amino group, a sulfhydryl group, and/or a hydroxyl group. The photolabile compound, upon absorbing visible light, releases the organic moiety. Also disclosed is a method of making a photolabile compound that releases a biologically active compound upon absorbing visible light by providing an organic moiety and binding a coumarin family caging group to the organic moiety under conditions effective to make the photolabile compound. The present invention also relates to a method of obtaining a biologically active compound in a sample. The method involves adding to a sample a photolabile compound including a coumarin family caging group covalently bound to an organic moiety. The sample is then illuminated with visible light under conditions effective to obtain a biologically active compound including the organic moiety.

Abstract: The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.

Abstract: A polarizer is provided comprising a subwavelength optical microstructure wherein the microstructure is partially covered with a light-transmissive inhibiting surface for polarizing light. The inhibiting surface can include a reflective surface, such as a metalized coating. The subwavelength optical microstructure can include moth-eye structures, linear prisms, or modified structures thereof. A polarizing structure is further provided comprising a plurality of moth-eye structures stacked on one another for polarizing light.

Abstract: A method, computer readable medium and system for capacity management and predictive planning includes monitoring one or more factors related to an overall load on at least one of one or more server systems and trending a rate of change of at least one of the one or more monitored factors. A determination on when to at least one of increase capacity in at least one of the servers systems and add one or more additional server systems is made based on the monitoring and the trending.

Abstract: A method for assaying a biological sample includes forming sensitized microcapsules filled with unique oligomarkers, capturing sensitized microcapsules in the presence of analytes, releasing oligomarkers from microcapsules and detecting and measuring oligomarkers to detect and quantify presence of analyte in biological sample. Using encapsulated oligomarkers provides for an amplified high sensitivity assay and using plurality of oligomarker types provides for a multiplexed assay.

Abstract: The present invention relates to a method for preparing photoluminescent silicon nanoparticles having uniformly hydrogen-terminated surfaces that are essentially free of residual oxygen. The present invention also relates to a method of preparing a blue-emitting photoluminescent silicon nanoparticle. The present invention further relates to a composition that includes a photoluminescent silicon nanoparticle having a surface that is uniformly hydrogen-terminated and essentially free of residual oxygen. The present invention also relates to a composition including a photoluminescent silicon nanoparticle having a surface that is uniformly coated with an organic layer and essentially free of residual oxygen. The present invention additionally relates to a composition including a photoluminescent silicon nanoparticle stably dispersed in an organic solvent and having a surface that is uniformly coated with an organic layer and essentially free of residual oxygen.

Abstract: Compounds of formula (I) wherein R1 and R2 are the same or different and are each optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl groups; R3 is hydrogen or an aryl group substituent or R3 is a solid support optionally attached via a spacer; Z represents an oxygen atom, a sulphur atom or NR4; Y represents an oxygen atom, a sulphur atom or NR5; in which R4 and R5, which may be the same or different, represent hydrogen, optionally substituted alkyl containing 1 to 6 carbon atoms, optionally substituted phenyl, optionally substituted benzyl or optionally substituted ?-phenylethyl; and one of X1 and X2 represents a nitrogen atom and the other of X1 and X2 represents a nitrogen atom or CR6, in which R6 represents hydrogen or an aryl group substituent; are useful for the affinity binding of a prion protein.

Abstract: The invention relates to a modified hydrocarbylphenol-aldehyde resin prepared by reacting a hydrocarbylphenol-aldehyde resin with a primary or secondary amine and further with an epoxide. The invention also provides a process for preparing a modified, hydrocarbylphenol-aldehyde resin and a rubber composition containing such resin.

Abstract: The present invention relates to a rosamine derivative compound, as described herein, having the following structure: Also disclosed are methods of making such compounds and for using them for detection and imaging.